Comparable High-Grade Toxicity with Axi-Cel Plus Dexamethasone Prophylaxis Versus Liso-Cel: A Real-World Analysis

Key Points

• Axi-cel with dexamethasone shows comparable high-grade toxicity to Liso-cel in patients treated with CAR T therapy.
• Patients receiving Axi-cel experienced 72% high-grade toxicity incidence, matching Liso-cel outcomes closely.
• Analysis based on real-world data assessing treatments reveals significant implications for patient management.
• Findings suggest the need for careful monitoring and potential adjustments in toxicity management strategies.